KEAP1/NRF2 (NFE2L2) mutations in NSCLC – Fuel for a superresistant phenotype?
Introduction
The transcription factor NRF2 (nuclear factor E2-related factor 2) (also known as nuclear factor, erythroid 2 like 2 [NFE2L2]) is the master regulator of cellular antioxidant responses. NRF2 is repressed by interaction with a redox-sensitive protein KEAP1 (Kelch-like ECH-associated protein 1). The KEAP1/NRF2 pathway is an important signaling cascade responsible for cellular resistance to oxidative damage induced by exogenous chemicals and electrophiles in almost all cell types [1], [2].
Dysregulation of KEAP1/NRF2 transcriptional activity has been associated with the pathogenesis of multiple diseases, and the KEAP1/NRF2 axis has emerged to be the most important modulator of cellular homeostasis. NRF2 is highly sensitive to oxidative and electrophilic products, including reactive oxygen species (ROS) and reactive nitrogen species (RNS). In the cell nucleus, NRF2 activates various antioxidant and related genes by binding to antioxidant-responsive elements (AREs) or electrophile-responsive elements (EpREs) (consensus sequence: 5‘-TGACNNNGC-3′). NRF2 then in turn activates genes that regulate redox homeostasis, drug metabolism and excretion, energetic metabolism, iron metabolism, amino acid metabolism, survival, proliferation, autophagy, proteasomal degradation, DNA repair, and mitochondrial physiology [3].
Oxidative stress plays an important role in the initiation and progression of many chronic diseases, including diabetes, cancer, and neurodegenerative diseases [4], [5], [6], [7], and regulation of cytoprotective gene expression by KEAP1/NRF2 is the principal inducible defense mechanism against oxidative and electrophilic cellular stresses [8], [9] (Fig. 1).
The KEAP1/NRF2 axis has also been recognized as a central cornerstone for a cross-talk of cellular defense and survival pathways. NRF2 has been found to control expression of over 1,000 protective genes [12], [13], which comprise more than 1% of the human genome [14]. In addition, KEAP1 is a well-conserved protein, sharing around 95% of sequence homology between species [15] underpinning its important role in cellular defense mechanisms. Of note, in normal unstressed conditions, cellular NRF2 levels are very low (turnover: 20–30 min) [1], but are dramatically increased upon exposure to different stress levels of electrophilic chemicals, RNS, or ROS (concentration-dependent effects: cytostatic → tumorigenic → cytotoxic) [16].
Several lines of evidence have added further weight to the proposal that the KEAP1/NRF2 pathway is the key driver of cancer progression, metastasis, and resistance to tumor therapy. Interestingly, recent research has revealed that the KEAP1/NRF2 axis may have a contradictory role in cancers. Although this pathway is the main component of drug detoxification in normal cells, it also can be hijacked by malignant cells to evade the efficacy of various cancer treatments [2].
In this review we highlight the molecular features, the key components, and possible inhibitors of the KEAP1/NRF2 pathway, its role as prognostic and predictive biomarker, and the resulting clinical implications in NSCLC patients.
Section snippets
Molecular biology
Under normal conditions, NRF2 interacts with two KEAP1 molecules through the ETGE and DLG motifs in its Neh2 domain to activate the cullin 3 (Cul3)-based E3 ligase complex-mediated NRF2 ubiquitination reaction [2]. Cul3 serves as a scaffold for the E3 ligase RBX1. After NRF2 is ubiquitinated, it is rapidly degraded by 26S proteasome and maintained at a very low level in the cytoplasm [1].
Once cells are exposed to oxidative stress or chemo preventive compounds, electro-philes and ROS react with
KEAP1/NRF2 mutations in NSCLCs: A distinct clinical phenotype
Several lines of clinical research have provided evidence that NSCLC patients harboring KEAP1/NRF2 mutation exert a distinct clinicopathological phenotype [30], [55]. Mutations in the KEAP1/NRF2 complex occur in 23% of lung adenocarcinomas [54] and in 34% of squamous cell carcinomas [57]. They are the most often observed NSCLC mutations behind p53 and K-ras. In addition, mutations are generally mutually exclusive and only in a minor proportion of patients other druggable targets can be
KEAP1/NRF2 inhibitors
Developing of KEAP1/NRF2 inhibitors has become one of the most attractive strategies for anticancer therapies during the past 10 years, but has sent many pharmaceutical companies to the graveyard in the last decade. The characterization of the crystal structure of KEAP1 in complex with the Neh2 domain of NRF2 has now offered new opportunities to design molecules that specially and selectively interfere with the binding of the KEAP1/NRF2 complex [59], but NRF2 has a very short half-life, even
Conclusion
The KEAP1/NRF2 system appears to be a very promising intracellular pathway to target common pathologic mechanisms of many chronic diseases and cancers including NSCLC. In this regard inhibitors of KEAP1 and/or NRF2 are expected to function as anticancer drugs. However, it needs to be taken into account that the role of NRF2 activation in cancer is paradoxical and does require further exploration as NRF2 inducers act to protect normal cells from carcinogens, whereas NRF2 inhibitors act to
Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Acknowledgement
The authors are indebted to Alwin Hierl (Munich, Germany) for preparing the art work.
References (64)
- et al.
Can activation of NRF2 be a strategy against COVID-19?
Trends Pharmacol Sci
(2020) - et al.
Beyond repression of Nrf2: an update on Keap1
Free Radic. Biol. Med.
(2020) - et al.
An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements
Biochem. Biophys. Res. Commun.
(1997) - et al.
Clinical implications of KEAP1-NFE2L2 mutations in NSCLC
J. Thorac. Oncol.
(2021) - et al.
Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab
Lung Cancer
(2021) - et al.
Mutations in the KEAP1-NFE2L2 pathway define a molecular subset of rapidly progressing lung adenocarcinoma
J. Thorac. Oncol.
(2019) - et al.
Mutations associated with sensitivity or resistance to immunotherapy in mNSCLC: analysis from the MYSTIC trial
J. Thorac. Oncol.
(2019) - et al.
KEAP1-NFE2L2-mutant NSCLC and immune checkpoint inhibitors: a large data-base analysis
J. Thorac. Oncol.
(2020) - et al.
PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab
Lung Cancer
(2021) - et al.
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden
Ann. Oncol.
(2020)
Impact of KEAP1/NFE2L2/CLU3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer
Lung Cancer
The role of NF-E2-related factor 2 in predicting chemoresistance and prognosis in advanced non-small cell lung cancer
Clin. Lung Cancer
ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response
Mol. Cell.
Playing the end game: DNA double-strand break repair pathway choice
Mol. Cell
Novel roles of c-MET in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression
J. Biol. Chem.
Phosphorylation of p62 activates the KEAP1-Nrf2 pathway during selective autophagy
Mol. Cell.
Mutations in the antioxidant KEAP1/NRF2 pathway define an aggressive subset of NSCLC resistant to conventional treatments
J Thorac. Oncol
CPUY192018, a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, alleviates renal inflammation in mice by restricting oxidative stress and NF-κB activation
Redox Biol.
The KEAP1-NRF2 system in cancer
Front. Oncol.
Nrf2 in cancers: a double-edged sword
Cancer Med.
NRF2 and the hallmarks of cancer
Cancer Cell
Oxidative stress
Annu. Rev. Biochem.
Modulation of oxidative stress as an anticancer strategy
Nat. Rev. Drug Discov.
Neurodegenerative diseases and oxidative stress
Nat. Rev. Drug Discov.
Keap1-Nrf2 signaling pathway in angiogenesis and vascular diseases
J. Tissue Eng. Med.
The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis
Physiol. Rev.
The molecular mechanisms regulating the KEAP1-NRF2 pathway
Mol Cell. Biol.
Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis
Nucl. Acid. Res.
Regulatory flexibility in the Nrf2-mediated stress response is conferred by conformational cycling of the Keap1-Nrf2 protein complex
Proc. Natl. Acad USA
Identification of the interactive interface and phylogenic conservation of the Nrf2-Keap1 system
Genes Cells
SCF/β-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner
Mol. Cell. Biol.
Cited by (18)
Targeting kelch-like (KLHL) proteins: achievements, challenges and perspectives
2024, European Journal of Medicinal ChemistryKEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC
2023, Journal of Thoracic Oncology
- 1
Both authors contributed equally to the paper.